Mineralys Therapeutics

MLYS

Market cap $3.17B

Overview Fund Trends Analyst Outlook Journalist POV

40.86 USD

--0.26

0.63%

At close Updated Oct 31, 4:00 PM EDT

Pre-market

After hours

40.99

+0.13

0.32%

1 day

-0.63%

5 days

1.49%

1 month

7.75%

3 months

188.76%

6 months

187.54%

Year to date

233.55%

1 year

205.38%

5 years

121.58%

10 years

121.58%

About: Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Employees: 51

Healthcare Biotechnology